Tarcenib 150 mg (Tablet)
Unit Price: ৳ 600.00 (1 x 10: ৳ 6,000.00)
Strip Price: ৳ 6,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Techno drugs ltd |
| Also available as |
Indications
- First-line treatment of metastatic Non-Small Cell Lung cancer (NSCLC)
- Maintenance treatment of locally advanced or metastatic NSCLC
- Treatment of locally advanced or metastatic NSCLC after failure of prior chemotherapy regimen
- First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer
Description
- Chemical name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
- Kinase inhibitor
- Reversibly inhibits EGFR kinase activity
- Prevents autophosphorylation of tyrosine residues
- Higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations
Dosage & Administration
- Recommended daily dose for NSCLC: 150 mg on an empty stomach
- Recommended daily dose for pancreatic cancer: 100 mg in combination with gemcitabine
- Dose reduction for severe reactions with co-administration of strong CYP3A4 inhibitors
- Dose increase for concomitant use with CYP3A4 inducers
Interaction
- Interaction with coumarin-derived anticoagulants
- Metabolized predominantly by CYP3A4
- Co-treatment with potent CYP3A4 inhibitor ketoconazole increased AUC by 67%
- Pre-treatment with CYP3A4 inducer Rifampicin decreased AUC by 58% to 80%
Side Effects
- Common adverse reactions: rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting
- Serious adverse reactions: Interstitial Lung Disease (ILD), Renal Failure, Hepatotoxicity, Gastrointestinal Perforation, Bullous and Exfoliative Skin Disorders, Myocardial Infarction/Ischemia, Cerebrovascular Accident
Pregnancy & Lactation
- Pregnancy category D
- Potential for serious adverse reactions in nursing infants
Precautions & Warnings
- 1.1% occurrence of Interstitial Lung Disease (ILD)
- Monitor renal function and electrolytes for patients at risk of dehydration
- Monitor periodic liver testing for hepatotoxicity
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No overall differences in safety or efficacy observed in patients 65 years and older
Overdose Effects
- Tolerated single oral doses up to 1,000 mg in healthy subjects
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store at a temperature not exceeding 30°C
- Protect from light and moisture